organ transplant News
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
-
LifeLink Tissue Bank Announces Partnership with NuTech Spine
LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, announced a new partnership with NuTech Spine and Biologics, in which NuTech will distribute LifeLink allografts to surgeons nationwide for patients in need of sports, orthopedic and spine transplants. Additionally, LifeLink will process custom spine allografts for distribution. Jean Davis, President and ...
-
CELLVIE’s mitochondria treatment has been granted orphan-drug designation from the FDA
The Orphan Drug Act, a law passed in 1983, provides for granting special status to a drug or biological product to treat a rare disease or condition, with the goal being accelerated evaluation and development of promising medical products. This special orphan drug status comes with multiple benefits: Eligibility for market exclusivity for 7 years post approval Tax credits of 50% off the ...
By cellvie Inc.
-
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. BIOLIFE4D has raised more than $3M in equity crowdfunding investments since February of 2018. BIOLIFE4D’s modified Regulation A+ offering will allow the company to ...
By BIOLIFE4D
-
SQI Diagnostics - Lung Health Diagnostic Testing
Eric Brouwer, Ph.D., Chief Scientific Officer at SQI Diagnostics, a company focused on the science of lung health, discusses the development and manufacture of respiratory health and precision medicine tests. Their tests simplify and improve COVID-19 mobile PCR, Point of Care antigen testing and antibody monitoring, Rapid Acute Lung Injury testing, donor organ transplant informatics, and ...
-
`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug
Bilirubin, which causes jaundice in humans, has been in the spotlight as an anti-inflammatory substance since the 1930s. The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the Nobel Prize in Physiology or Medicine. Attempts to drug ...
-
Bilirubin, which eliminates inflammation... Bilix, the world`s first drug
Discovered in the 1930s... fail every time Chemicalized by combining with hydrophilic substances “To develop a treatment for reperfusion injury” Since the 1930s, 'bilirubin', which causes jaundice in humans, has been in the limelight as an anti-inflammatory substance. The phenomenon in which rheumatoid arthritis patients get jaundice causes rheumatoid inflammation to disappear when ...
-
Long-term outcomes after standard graft-versus-host disease
Neovii is pleased to announce the publication of the long-term outcomes of a multicenter parallel-group randomized trial conducted in Europe and Israel. The study looked at patients after standard GvHD prophylaxis with cyclosporine A and methotrexate with or without Grafalon® (anti-human-T-lymphocyte immunoglobulin- ATLG) (60 mg/kg total dose) in adult patients receiving myeloablative ...
-
Reprise Biomedical Completes Spin-off from Miromatrix Medical
Reprise Biomedical, Inc., a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology, has successfully completed a $12.5 million private placement and commenced operations as a spin-off from Miromatrix Medical Inc. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, ...
-
CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
CD Genomics is a leading global life sciences company committed to providing the research community with high-quality long-read sequencing services, from Oxford Nanopore to PacBio SMRT sequencing. The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient ...
By CD Genomics
-
Berlin Heart triples staff member donations and secures `Films for life` project financing
For many Berlin Heart staff members, providing ventricular assist devices for people who are waiting for a donor heart is more than just a job. Extending the lives of patients and giving them quality of life despite all circumstances is the motivation that drives many Berlin Heart staff members on a daily basis. Raising awareness for the issue of organ donation is therefore close to their hearts, ...
-
Biostage Hires David Green as Chief Executive Officer
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced it has hired David Green as its Chief Executive Officer and appointed Mr. Green as Chairman of the Board of Directors (the ...
-
Leadership change and even more momentum: Biotech pioneer Neovii under new management
Dr. Christian Loss (57), former managing director of Neovii Biotech GmbH, Gräfelfing, is moving to the Swiss headquarters of Neovii Pharmaceuticals AG in Rapperswil as chief executive officer (CEO). As the new CEO in Germany, he will be succeeded by the former Neovii Head of Production, Sebastian Hofmann (40). With the change in management, two long-serving and experienced employees remain ...
-
Billix, 14 billion Series A round closing
Billix has successfully completed the Series A round. It raised 14 billion won in an investment round in a year and a half. Not only financial investors (FI) but also strategic investors (SI) such as Estec Pharma and Soulbrain Holdings continued to participate. According to related industries on the 25th, Bilix recently completed attracting 14 billion won in Series A investment. As a result, the ...
-
NEC OncoImmunity publishes a unique HLA typing technology that discovers new HLA alleles, and tumor specific HLA alleles
The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI. NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Invizius named ‘Best Innovative MedTech’
Invizius, a University of Edinburgh spinout whose technology promises to improve the lives of millions of dialysis patients, has been named Best Innovative MedTech company at the prestigious OBN Awards. The company’s success in the awards, which have a high profile in the life sciences sector, follows on from a seed investment of £500,000 from Mercia Fund Managers in May 2018. ...
-
A new type of corneal availability
Although around 200,000 corneal transplants are performed worldwide each year – and corneal transplant is the most common organ transplant around the globe – close to 13 million people are still on a waiting list for a corneal graft (1), with average delays measured in years. EyeYon Medical, founded by two leading cornea specialists – Ofer Daphna and Arie Markovich – ...
-
OnLume Surgical Awarded $2 Million Grant from National Cancer Institute to Advance the Development of its Novel Fluorescence-Guided Surgery Device
OnLume Inc., an early stage medical imaging company with unique technology for improving surgical precision, has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). OnLume has developed novel FGS imaging technology to illuminate critical ...
By OnLume Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you